Hybrid TRUS/CT with optical tracking for target delineation in image-guided adaptive brachytherapy for cervical cancer.
Antineoplastic Agents, Alkylating
/ therapeutic use
Brachytherapy
/ methods
Carcinoma, Squamous Cell
/ diagnostic imaging
Chemotherapy, Adjuvant
Cisplatin
/ therapeutic use
Female
Humans
Magnetic Resonance Imaging
/ methods
Multimodal Imaging
/ methods
Observer Variation
Prospective Studies
Radiotherapy, Image-Guided
/ methods
Tomography, X-Ray Computed
/ methods
Ultrasound, High-Intensity Focused, Transrectal
/ methods
Uterine Cervical Neoplasms
/ diagnostic imaging
Contouring
Image-guided adaptive brachytherapy
Locally advanced cervical cancer
MRI
Transrectal ultrasound
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
20
12
2019
accepted:
13
06
2020
pubmed:
6
7
2020
medline:
15
12
2020
entrez:
5
7
2020
Statut:
ppublish
Résumé
To prospectively compare the interobserver variability of combined transrectal ultrasound (TRUS)/computed tomography (CT)- vs. CT only- vs. magnetic resonance imaging (MRI) only-based contouring of the high-risk clinical target volume (CTV Five patients with LACC (FIGO stages IIb-IVa) treated with radiochemotherapy and IGABT were included. CT, TRUS, and T2-weighted MRI images were performed after brachytherapy applicator insertion. 3D-TRUS image acquisition was performed with a customized ultrasound stepper device and software. Automatic applicator reconstruction using optical tracking was performed in the TRUS dataset and TRUS and CT images were fused with rigid image registration with the applicator as reference structure. The CTV The interobserver coefficient of variation was 0.18 ± 0.05 for CT, 0.10 ± 0.04 for TRUS-CT, and 0.07 ± 0.03 for MRI. Interobserver concordance in relation to the MRIref expressed by the generalized conformity index was 0.75 ± 0.04 for MRI, 0.51 ± 0.10 for TRUS-CT, and 0.48 ± 0.06 for CT. The mean CTV Hybrid TRUS-CT as an imaging modality for contouring the CTV
Identifiants
pubmed: 32621011
doi: 10.1007/s00066-020-01656-2
pii: 10.1007/s00066-020-01656-2
pmc: PMC7653783
doi:
Substances chimiques
Antineoplastic Agents, Alkylating
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
983-992Références
Radiother Oncol. 2008 Nov;89(2):164-71
pubmed: 18789829
Phys Med Biol. 2009 May 7;54(9):2863-73
pubmed: 19384002
Gynecol Oncol. 2014 Nov;135(2):231-8
pubmed: 25172763
Radiother Oncol. 2007 May;83(2):148-55
pubmed: 17531904
Brachytherapy. 2016 Nov - Dec;15(6):839-844
pubmed: 27693172
Strahlenther Onkol. 2020 Mar;196(3):222-228
pubmed: 31942652
Radiother Oncol. 2012 Apr;103(1):113-22
pubmed: 22296748
Acta Oncol. 2013 Oct;52(7):1510-9
pubmed: 23962242
Acta Oncol. 2013 Oct;52(7):1345-52
pubmed: 23905674
Radiother Oncol. 2015 Apr;115(1):78-83
pubmed: 25805517
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):71-7
pubmed: 16997500
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):491-8
pubmed: 17331668
Brachytherapy. 2014 Jan-Feb;13(1):75-9
pubmed: 24080299
Radiother Oncol. 2011 Jul;100(1):116-23
pubmed: 21821305
Rep Pract Oncol Radiother. 2015 May-Jun;20(3):223-30
pubmed: 25949227
Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):756-64
pubmed: 18191335
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):588-97
pubmed: 26867887
Strahlenther Onkol. 2019 Nov;195(11):972-981
pubmed: 31309266
Radiother Oncol. 2012 Jun;103(3):305-13
pubmed: 22633469
Int J Radiat Oncol Biol Phys. 2014 Oct 1;90(2):320-8
pubmed: 25304792
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:22-36
pubmed: 30306584
Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1448-1456
pubmed: 30146092
Med Phys. 2012 Oct;39(10):6332-8
pubmed: 23039669
Radiother Oncol. 2016 Sep;120(3):428-433
pubmed: 27134181
Strahlenther Onkol. 2013 Feb;189(2):123-8
pubmed: 23255091
Radiother Oncol. 2005 Mar;74(3):235-45
pubmed: 15763303
Radiother Oncol. 2016 Sep;120(3):467-472
pubmed: 26921168
Radiother Oncol. 2013 Apr;107(1):75-81
pubmed: 23068712